| Description |
bpV(phen) is a potent protein tyrosine phosphatase (PTP) and PTEN inhibitor with IC50s of 38 nM, 343 nM and 920 nM for PTEN, PTP-β and PTP-1B. bpV(phen) is an insulin-mimetic agent following insulin-receptor tyrosine kinase hyperphosphorylation and activation. bpV(phen) activates HIV-1 transcription and replication via NF-κB-dependent and independent mechanisms. bpV(phen) inhibits proliferation of the protozoan parasite Leishmania in vitro. bpV(phen) strongly induces the secretion of a large number of chemokines and pro-inflammatory cytokines, and it activates a Th1-type pathway (IL-12, IFNγ). bpV(phen) can also induce cell apoptosis, and has anti-angiogenic and anti-tumor activity[1][2][3][4][5].
|
| Related Catalog |
|
| Target |
IC50: 38 nM (PTEN), 343 nM (PTP-β) and 920 nM (PTP-1B)[3] Parasite Leishmania[2] HIV-1[2] Apoptosis[1]
|
| In Vitro |
bpV(phen) (5 μM; 24.5 hours; H9c2 cells) treatment causes a further decrease of cell viability in H/R-injured H9c2 cells[1]. bpV(phen) (5 μM; 24.5 hours; H9c2 cells) treatment increases the apoptosis of H/R-injured H9c2 cells[1]. bpV(phen) (5 μM; 24.5 hours; H9c2 cells) treatment significantly promotes the accumulation of cytoplasmic Cytochrome C in H/R-injured H9c2 cells[1]. After stimulation of bpV(phen), PTEN-induced putative kinase protein 1 (PINK1)/Parkin-mediated mitophagy is inhibited[1]. Cell Viability Assay[1] Cell Line: Hypoxia/reoxygenation (H/R)-injured H9c2 cells Concentration: 5 μM Incubation Time: 24.5 hours (hypoxia for 24 h; reoxygenation for 30 minutes) Result: Caused a further decrease of cell viability. Apoptosis Analysis[1] Cell Line: Hypoxia/reoxygenation (H/R)-injured H9c2 cells Concentration: 5 μM Incubation Time: 24.5 hours (hypoxia for 24 h; reoxygenation for 30 minutes) Result: Increased the apoptosis of H/R-injured H9c2 cells. Western Blot Analysis[1] Cell Line: Hypoxia/reoxygenation (H/R)-injured H9c2 cells Concentration: 5 μM Incubation Time: 24.5 hours (hypoxia for 24 h; reoxygenation for 30 minutes) Result: Showed an increased release of Cytochrome C.
|
| In Vivo |
bpV(phen) (5 mg/kg; intraperitoneal injection; daily; for 38 days; male BALB/c nude (nu/nu) athymic mice) treatment causes a significant reduction in average tumor volume[1]. Animal Model: Male BALB/c nude (nu/nu) athymic mice (6-7 weeks old) injected with PC-3 cells[2] Dosage: 5 mg/kg Administration: Intraperitoneal injection; daily; for 38 days Result: Caused a significant reduction in average tumor volume.
|
| References |
[1]. Tang W, et al. PTEN-mediated mitophagy and APE1 overexpression protects against cardiac hypoxia/reoxygenation injury. In Vitro Cell Dev Biol Anim. 2019 Oct;55(9):741-748. [2]. Caron D, et al. Protein tyrosine phosphatase inhibition induces anti-tumor activity: evidence of Cdk2/p27 kip1 and Cdk2/SHP-1 complex formation in human ovarian cancer cells. Cancer Lett. 2008 Apr 18;262(2):265-75. [3]. Schmid AC, et al. Bisperoxovanadium compounds are potent PTEN inhibitors. FEBS Lett. 2004 May 21;566(1-3):35-8. [4]. Band CJ, et al. Early signaling events triggered by peroxovanadium [bpV(phen)] are insulin receptor kinase (IRK)-dependent: specificity of inhibition of IRK-associated protein tyrosine phosphatase(s) by bpV(phen). Mol Endocrinol. 1997 Dec;11(13):1899-910. [5]. Chen Q, et al. Potassium Bisperoxo(1,10-phenanthroline)oxovanadate (bpV(phen)) Induces Apoptosis and Pyroptosis and Disrupts the P62-HDAC6 Protein Interaction to Suppress the Acetylated Microtubule-dependent Degradation of Autophagosomes. J Biol Chem. 2015 Oct 23;290(43):26051-8.
|
